The absence of chemotherapy in the Basic NCCN RSG for BC conflicts with Basic NCCN RSG for colon cancer where adjuvant and palliative chemotherapy are recommended.19 The evidence supporting adjuvant chemotherapy for high-risk BC is clear,20,21 with survival benefits equal to or greater than for adjuvant chemotherapy for colon cancer.22 The NCCN BC guidelines also conflict with the BGHI9 RSGs and Asian Oncology RSGs for HER2-positive disease,23 which both support chemotherapy in the Basic setting. The gene discussed is ERBB2; the disease is breast cancer.